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Oxidative stress can cause DNA breaks which induce activation of the DNA nick sensor enzyme poly
(ADP-ribose) polymerase-1 (PARP-1), part of the 17 member PARP enzyme family. PARP-1 modiﬁes target
proteins by attaching to them several NAD-derived ADP-ribose units forming poly(ADP-ribose) (PAR)
polymers. PARylation controls many cellular processes while intense PARylation may also lead to cell
death by various mechanisms. Here we summarize the modes of activation, inhibitors and modulators of
PARP-1 and review the cellular functions regulated by the enzyme.
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Poly(ADP-ribosyl)ation (PARylation) is a protein modiﬁcation
catalyzed by poly(ADP-ribose) polymerase (PARP) enzymes. The
enzyme family was created based on database screening using the
highly conserved PARP signature motif. Whereas the PARP enzyme
family consists of 17 members [1], only three of these enzymes can
be considered as bona ﬁde PARPs while the other family members
function as mono(ADP-ribosyl) transferases or their enzymatic
activity has not yet been characterized. PARylation requires NAD as
substrate and this energy metabolite is cleaved into nicotinamide
and ADP-ribose by active PARP enzymes. In turn, PARPs attach theB.V. This is an open access article
Chemistry, Faculty of Medi-
32 Debrecen, Hungary.ﬁrst ADP-ribose unit to appropriate substrates and then generate
further ADP-ribose units by repeated NAD cleavage and polymer-
ize ADP-ribose moieties [2].
Here we review the mechanisms by which activity of PARP-1
can be stimulated, inhibited or modulated. We also aim to
summarize the cellular functions that are regulated by PARP-1.Routes for PARP-1 activation
PARP-1 has originally been described as a DNA nick sensor
enzyme activated by DNA single and double strand breaks [3]. DNA
damage-induced PARP-1 activation is considered as the classical
route for the activation of the enzyme (Fig. 1). PARP-1 binds to
broken DNA ends via the zinc ﬁnger motives found in the
N-terminal DNA binding domain. Reactive oxygen and nitrogenunder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. Activation of PARP-1. The nuclear enzyme PARP-1 can bind to DNA breaks resulting in the activation of the enzyme. DNA breaks are caused either by direct attacks by
ROS, RNS or ionizing radiation or may form indirectly when the DNA repair machinery introduces breaks into the DNA strands following e.g. alkylating DNA damage. Binding
to non-B DNA structures such as bent or cruciform DNA or four-way junctions may also lead to PARP-1 activation. DNA independent activation mechanisms have also been
described for PARP-1. These include protein–protein interactions or covalent modiﬁcations (e.g. mono-ADP-ribosylation, acetylation or phosphorylation) (for details and
references see text).
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many ROS/RNS species are capable of causing DNA single strand
breaks [4]. Ionizing radiations may also cause DNA breaks either
directly (e.g. alpha particles or neutrons which have high linear
energy transfer) or indirectly (via interactionwith water resulting in
the production of hydroxyl radicals). Moreover, repair of damage
caused by alkylating agents [e.g. N-methyl-N-nitro-N-nitrosoguani-
dine (MNNG), N-nitroso-N-methylurea (MNU), temozolomide, and
carmustine] also feed into this route as DNA repair machineries (e.g.
base excision repair and nucleotide excision repair) introduce cuts
(single or double strand breaks) leading to PARP-1 activation [5].
The ﬁndings that stimuli other than broken DNA can also activate
PARP-1 (Fig. 1) led to a paradigm shift in the investigation of the
enzyme [6]. Lonskaya et al. showed that PARP-1 can bind to non-B
DNA structures (three- and fourway junctions, hairpins, cruciforms
and stably unpaired regions) resulting in activation of the enzyme
[7]. Moreover, the enzyme may be activated by interactions with
partner proteins (Fig. 1). For example interaction with the N-terminal
tail of histone 4 has been shown to activate PARP-1 [8]. Moreover,
physical interaction between PARP-1 and the phosphorylated form of
Erk MAP kinase also activates PARP-1 [9,10]. Furthermore, protein
modiﬁcations, e.g. phosphorylation by certain protein kinases such as
CamKII delta [11], mono-ADP-ribosylation by SIRT6 [12,13] or PARP-3
[14] or acetylation can also stimulate PARP-1 activity [15] (Fig. 1). Of
note, a basal phosphorylation by an unknown kinase was found to be
required for PARP-1 activity [16]. SIRT6 a mammalian homolog of the
yeast Sir2 deacetylase has been shown to be recruited to the sites of
oxidative DNA damage (double strand breaks) where it associates
with PARP1 and activates it by mono-ADP-ribosylation [13]. PARP-3
can also catalyze activating mono(ADP-ribosyl)ation of PARP-1 but
this reaction takes place in the absence of DNA [14]. PARP-1 has also
been shown to be a target of acetylation [17]. Acetylation of PARP-1
may contribute to the maintenance of the active state of the enzyme
as deacetylation by SIRT-1 downregulated the activity of PARP-1 [15].Inhibitors and modulators of PARP-1
Several classes of compounds with PARP inhibitory properties
have been developed and characterized. Their discussion would go
way beyond the scope of this review so we only refer to excellent
reviews on PARP inhibitors and their therapeutic potentials [18–
20]. In addition to bona ﬁde PARP inhibitors several other
molecules have been demonstrated to exhibit PARP inhibitory
effects [21,22]. These include arsenite [23] (Fig. 2), tetracyclines
[24], ﬂavones, ﬂavonoles [25], purines [26], unsaturated fatty acids
[21], vitamin D3 [27], vitamin A and vitamin K [21]. However, the
biological relevance of the PARP inhibitory properties of these
exogenous or endogenous molecules with special regard to the
relationship between their cellular concentrations and their Ki
values remains to be determined.
A much more interesting issue is the interference between
certain signaling events and PARP activation (Fig. 2). Above we
discussed phosphorylation as one of the PARP-1 activating stimuli.
However, phosphorylation of PARP-1 by kinases such as DNA-PK
[28] or protein kinase C has been shown to inhibit the activity of
the enzyme [29,30]. This ﬁnding translates to cellular conse-
quences as it has later been demonstrated that activation of PKC
by phorbol esters led to inhibition of oxidative stress-induced
PARP activation and resulted in suppressed PARP-dependent
cytotoxicity [31]. Calcium signal, a temporarily elevated cytosolic
calcium concentration may also be required for oxidative stress-
induced PARP activation [32,33]. Calcium chelators prevent oxida-
tive stress-induced PARP-1 activation (Fig. 2), however the exact
nature of the relationship between the calcium signal and PARP
activity remains elusive. On the one hand PARP activity has been
shown to depend on calcium [34], while this relationship is partly
indirect: calcium chelation also suppressed oxidative-stress-in-
duced DNA breakage suggesting that calcium also plays a role at a
more proximal step of the oxidative stress-DNA breakage-PARP-1
Fig. 2. Inhibition of PARP-1. PARP-1 is an attractive pharmacological target in various diseases and therefore several classes of small molecule PARP inhibitors (not shown)
have been developed and tested successfully in cellular assays and animal models of diseases ranging from cancer, ischemia-reperfusion injury, stroke, sepsis to shock.
Several biomolecules such as ﬂavones, ﬂavonols, vitamins D3, A and K, purines and even unsaturated fatty acids have been described to possess PARP inhibitory activities.
Other bioactive compounds such as arsenite or tetracyclines also inhibit PARP-1. Inhibiting PARP activating signals such as calcium signal, activating phosphorylation by
certain kinases or zinc signaling may also lead to downregulation of PARP-1 activity. Of note, in the case of zinc chelators, it is not yet clear whether interference with the
signaling role of zinc or simply stripping off structural zinc ions from PARP-1 results in enzyme inhibition. Some phosphorylation events are not PARP-1 activating signals but
have inhibitory effects on the enzyme (for details and references see text).
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more complex, a late mitochondrial (?) calcium signal can also be
detected in oxidatively stressed cells and this late signal responds
well to PARP-1 inhibition or knockout [50].
Until recently calcium was the only ion considered to serve a
second messenger role. However, similar roles have later been
assigned to magnesium and zinc ions [36]. Interestingly, zinc
chelation suppressed PARP activation and subsequent cell death in
oxidatively stressed cells (Fig. 2) suggesting a possible link between
this transition metal ion and the enzyme [37]. PARP-1 binds to DNA
via its zinc ﬁngers so it may be plausible to hypothesize that the
zinc chelator withdraws the structure stabilizing zinc ion from the
zinc ﬁnger motives resulting in enzyme inhibition. In light of the
increasingly recognized signaling role of zinc, however, a scenario
described above for calcium may not be excluded either. According
to this hypothesis awaiting experimental conﬁrmation, zinc signal-
ing may converge on PARP-1 triggering its activation.
The role of several metabolites connected to PARP-1 including its
substrate (NAD), a key metabolite required for NAD synthesis (ATP)
and a product (nicotinamide) should not be disregarded as they have
also been shown to affect PARP activity [38]. Discussion of these
interrelationships, however, would go beyond the scope of this review.Cellular effects of PARP-1 activation
The effects of PARP-1 and PARylation are translated to cellular
responses in various different ways (Fig. 3). On the one hand
PARylation of PARP-1 (auto-PARylation) and other substrate pro-
teins (hetero-PARylation) alter the physicochemical properties of
the targets resulting in activation, inhibition or intracellular
translocation of the modiﬁed proteins. Moreover, non-covalentbinding of free or protein-bound polymer to proteins bearing one
of the PAR-binding motives also affects the function of the
targeted protein. Furthermore, PARP-1 can activate protein part-
ners via protein–protein interactions and by substrate competition
with other NAD-utilizing enzymes such as members of the Sir2
family of NAD-dependent deacetylases (Fig. 3).
The consequences of PARylation, PAR signaling, interaction of
PARP-1 with partner proteins and substrate competition affect
many cellular events ranging from genome organization [3,39],
transcription [39,40], replication [41] to DNA repair [42]. These
molecular pathways form the basis of such vital cellular functions
such as cell proliferation [43], differentiation [44–47], metabolism
and necroptotic cell death [35,48,49,51–53]. The combination of
cytoprotective effects and inhibition of transcription of inﬂamma-
tory mediators are considered central factors responsible for the
beneﬁcial effects of PARP inhibitors as demonstrated in various
models of inﬂammation and tissue injury [54,55,19].
From these intertwining networks of molecular events and
cellular functions here we would like to highlight one aspect bearing
the highest relevance to oxidative stress: regulation of oxidative
stress-induced cell death. The generally held view that in severe
oxidative stress situations unrepairable DNA damage induces exces-
sive PAR production and consequent NADþ and ATP consumption
has recently been challenged. Dawson's group has elegantly demon-
strated [56] that PARP-1-mediated inhibition of glycolysis is not
simply due to NAD consumption by PARP-1 but results from PAR
binding to hexokinase the ﬁrst regulated enzyme in the glycolytic
pathway causing hexokinase inhibition (Fig. 3) which slows down
glycolysis. The PARP-mediated cell death pathway is amenable to
pharmacological intervention as proven by numerous studies report-
ing cytoprotection by PARP inhibitor treatment applied in various
animal models of oxidative stress-related diseases [19,55].
Fig. 3. Cellular roles of PARylation. PARP-1 regulates molecular events by four mechanisms: (a) PARylation of target proteins; (b) non-covalent binding of free or protein-
bound PAR polymer to target proteins; (c) protein–protein interactions between PARP-1 and partner proteins; and (d) modulation of cellular levels of NAD and ATP. These
molecular events form the basis for the cellular roles of PARP-1 in the regulation of chromatin organization, transcription, replication, DNA repair and metabolism.
Combinations of these cellular effects are responsible for the regulatory roles of PARP-1 in cell differentiation, proliferation and cell death (for details and references see text).
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